Update on degenerative ataxias

Current Opinion in Neurology

Volumn 24, Issue 4, 2011, Pages 339-345

  Klockgether, Thomas ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

ataxia; clinical assessment methods; drug trial; MRI

Indexed keywords

ATAXIN 1; ATAXIN 2; ATAXIN 3; ATAXIN 7; FIBROBLAST GROWTH FACTOR 14; IDEBENONE; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; PRODYNORPHIN; PROTEIN KINASE C; RILUZOLE; TAU TUBULIN KINASE 2; THYMIDINE KINASE; THYMIDINE KINASE 2; TRANSGLUTAMINASE 6; UNCLASSIFIED DRUG;

ABETALIPOPROTEINEMIA; ATAXIA; AUTOSOMAL RECESSIVE DISORDER; CEREBELLUM DEGENERATION; CHROMOSOME 16Q; CLINICAL ASSESSMENT; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; DNA REPAIR; FRIEDREICH ATAXIA; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNE DEFICIENCY; MACHADO JOSEPH DISEASE; MOTOR NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; REVIEW; SPINOCEREBELLAR DEGENERATION;

ATAXIA; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 79960790152     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834875ba     Document Type: Review

References (49)

1. Tsuji S, Onodera O, Goto J, Nishizawa M. Sporadic ataxias in Japan: a population-based epidemiological study. Cerebellum 2008; 7:189-197.
2. Erichsen AK, Koht J, Stray-Pedersen A, et al. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain 2009; 132:1577-1588.
3. Sullivan EV, Rose J, Pfefferbaum A. Physiological and focal cerebellar substrates of abnormal postural sway and tremor in alcoholic women. Biol Psychiatry 2010; 67:44-51.
4. Galvin R, Brathen G, Ivashynka A, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol 2010; 17:1408-1418.
5. Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 2010; 67:330-335.
6. Greenlee JE, Clawson SA, Hill KE, et al. Antineuronal autoantibodies in paraneoplastic cerebellar degeneration associated with adenocarcinoma of the prostate. J Neurol Sci 2010; 291:74-78.
7. Chapireau D, Adlam D, Cameron M, Thompson M. Paraneoplastic syndromes in patients with primary oral cancers: a systematic review. Br J Oral Maxillofac Surg 2010; 48:338-344.
8. Hoosien M, Vredenburgh J, Lanfranco J, et al. A myxoid chondrosarcoma associated with an anti-Hu-positive paraneoplastic encephalomyelitis. J Neurooncol 2011; 101:135-139.
9. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18:19-23.
10. Marignier R, Chenevier F, Rogemond V, et al. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol 2010; 67:627-630.
11. Burk K, Wick M, Roth G, et al. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol 2010; 257:59-62.
12. Anheim M, Fleury M, Monga B, et al. Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. Neurogenetics 2010; 11:1-12.
13. Vermeer S, Hoischen A, Meijer RP, et al. Targeted next-generation sequencing of a 12.5Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia. Am J Hum Genet 2010; 87:813-819.
14. Fiskerstrand T, H'mida-Ben Brahim D, Johansson S, et al. Mutations in ABHD12 cause the neurodegenerative disease PHARC: an inborn error of endocannabinoid metabolism. Am J Hum Genet 2010; 87:410-417.
15. Assoum M, Salih MA, Drouot N, et al. Rundataxin, a novel protein with RUN and diacylglycerol binding domains, is mutant in a new recessive ataxia. Brain 2010; 133:2439-2447.
16. Kumari D, Biacsi RE, Usdin K. Repeat expansion affects both transcription initiation and elongation in Friedreich ataxia cells. J Biol Chem 2011; 286:4209-4215.
17. Leidgens S, De SS, Foury F. Frataxin interacts with Isu1 through a conserved tryptophan in its beta-sheet. Hum Mol Genet 2010; 19:276-286.
18. Huang ML, Becker EM, Whitnall M, et al. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci USA 2009; 106:16381-16386.
19. Irazusta V, Obis E, Moreno-Cermeno A, et al. Yeast frataxin mutants display decreased superoxide dismutase activity crucial to promote protein oxidative damage. Free Radic Biol Med 2010; 48:411-420.
20. Rai M, Soragni E, Chou CJ, et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One 2010; 5:e8825.
21. Coppola G, Marmolino D, Lu D, et al. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia. Hum Mol Genet 2009; 18:2452-2461.
22. Gonzalez-Cabo P, Ros S, Palau F. Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency. PLoS One 2010; 5:e8872.
23. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol 2010; 67:941-947.
24. Anheim M, Monga B, Fleury M, et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90. patients. Brain 2009; 132:2688-2698.
25. Suraweera A, Lim Y, Woods R, et al. Functional role for senataxin, defective in ataxia oculomotor apraxia type 2, in transcriptional regulation. Hum Mol Genet 2009; 18:3384-3396.
26. Bakalkin G, Watanabe H, Jezierska J, et al. Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23. Am J Hum Genet 2010; 87:593-603.
27. Di Bella A, Lazzaro F, Brusco A, et al. Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet 2010; 42:313-321.
28. Sato N, Amino T, Kobayashi K, et al. Spinocerebellar ataxia type 31 is associated with 'inserted' penta-nucleotide repeats containing (TGGAA)n. Am J Hum Genet 2009; 85:544-557.
29. Wang JL, Yang X, Xia K, et al. TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. Brain 2010; 133:3510-3518.
30. Prakash N, Hageman N, Hua X, et al. Patterns of fractional anisotropy changes in white matter of cerebellar peduncles distinguish spinocerebellar ataxia-1 from multiple system atrophy and other ataxia syndromes. Neuroimage 2009; (Suppl 2):T72-T81.
31. Solodkin A, Peri E, Chen EE, et al. Loss of intrinsic organization of cerebellar networks in spinocerebellar ataxia type 1: correlates with disease severity and duration. Cerebellum 2010 [Epub ahead of print].
32. Oz G, Hutter D, Tkac I, et al. Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov Disord 2010; 25:1253-1261.
33. Schulz JB, Borkert J, Wolf S, et al. Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. Neuroimage 2010; 49:158-168.
34. Reetz K, Kleiman A, Klein C, et al. CAG repeats determine brain atrophy in spinocerebellar ataxia 17: a VBM study. PLoS One 2011; 6:e15125.
35. Alcauter S, Barrios FA, Diaz R, Fernandez-Ruiz J. Gray and white matter alterations in spinocerebellar ataxia type 7: an in vivo DTI and VBM study. Neuroimage 2011; 55:1-7.
36. Wardle M, Majounie E, Muzaimi MB, et al. The genetic aetiology of late-onset chronic progressive cerebellar ataxia: a population-based study. J Neurol 2009; 256:343-348.
37. Ota S, Tsuchiya K, AnnoM, et al. Distribution of cerebello-olivary degeneration in idiopathic late cortical cerebellar atrophy: clinicopathological study of four autopsy cases. Neuropathology 2008; 28:43-50.
38. Schmahmann JD, Gardner R, MacMore J, Vangel MG. Development of a brief ataxia rating scale (BARS) based on a modified form of the ICARS. Mov Disord 2009; 24:1820-1828.
39. Burk K, Malzig U, Wolf S, et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord 2009; 24:1779-1784.
40. Schmitz-Hubsch T, Fimmers R, Rakowicz M, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010; 74: 678-684.
41. Friedman LS, Farmer JM, Perlman S, et al. Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord 2010; 25:426-432.
42. Ilg W, Synofzik M, Brotz D, et al. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 2009; 73:1823-1830.
43. Ilg W, Brotz D, Burkard S, et al. Long-term effects of coordinative training in degenerative cerebellar disease. Mov Disord 2010; 25:2239-2246.
44. Corben LA, Tai G, Wilson C, et al. A comparison of three measures of upper limb function in Friedreich ataxia. J Neurol 2010; 257:518-523.
45. Chan E, Charles P, Ribai P, et al. Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Mov Disord 2011; 26:534-538.
46. Paulsen EK, Friedman LS, Myers LM, Lynch DR. Health-related quality of life in children with Friedreich ataxia. Pediatr Neurol 2010; 42:335-337.
47. Schmitz-Hubsch T, Coudert M, Giunti P, et al. Self-rated health status in spinocerebellar ataxia: results from a European multicenter study. Mov Disord 2010; 25:587-595.
48. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010; 74:839-845.
49. Silva RC, Saute JA, Silva AC, et al. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Braz J Med Biol Res 2010; 43:537-542.